Literature DB >> 15124704

The U.S. trials in adult acute lymphoblastic leukemia.

R A Larson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15124704     DOI： 10.1007/s00277-004-0850-2

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  7 in total

1.  Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.

Authors:  Wendy Stock; Jeffrey L Johnson; Richard M Stone; Jonathan E Kolitz; Bayard L Powell; Meir Wetzler; Peter Westervelt; Guido Marcucci; Daniel J DeAngelo; James W Vardiman; Diane McDonnell; Krzysztof Mrózek; Clara D Bloomfield; Richard A Larson
Journal:  Cancer       Date:  2012-06-28       Impact factor: 6.860

2.  Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Authors:  Michaela Liedtke; Clare J Twist; Bruno C Medeiros; Jason R Gotlib; Caroline Berube; Marcia M Bieber; Neelima M Bhat; Nelson N Teng; Steven E Coutre
Journal:  Haematologica       Date:  2011-10-11       Impact factor: 9.941

3.  SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.

Authors:  Anjali S Advani; Anna Moseley; Kristen M O'Dwyer; Brent L Wood; Min Fang; Matthew J Wieduwilt; Ibrahim Aldoss; Jae H Park; Rebecca B Klisovic; Maria R Baer; Wendy Stock; Rupali R Bhave; Megan Othus; Richard C Harvey; Cheryl L Willman; Mark R Litzow; Richard M Stone; Elad Sharon; Harry P Erba
Journal:  J Clin Oncol       Date:  2022-02-14       Impact factor: 50.717

Review 4.  Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodies.

Authors:  Naval Daver; Susan O'Brien
Journal:  Curr Hematol Malig Rep       Date:  2013-06       Impact factor: 3.952

5.  What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies.

Authors:  Wendy Stock; Mei La; Ben Sanford; Clara D Bloomfield; James W Vardiman; Paul Gaynon; Richard A Larson; James Nachman
Journal:  Blood       Date:  2008-05-23       Impact factor: 22.113

6.  Up-regulation of P-glycoprotein confers acquired resistance to 6-mercaptopurine in human chronic myeloid leukemia cells.

Authors:  Xing-Xiang Peng; Zhi Shi; Amit K Tiwari; Vijaya L Damaraju; Liwu Fu; Carol E Cass; Charles R Ashby; Gary D Kruh; Zhe-Sheng Chen
Journal:  Oncol Lett       Date:  2011-03-21       Impact factor: 2.967

7.  Novel Bruton's tyrosine kinase inhibitors currently in development.

Authors:  Osmond J D'Cruz; Fatih M Uckun
Journal:  Onco Targets Ther       Date:  2013-03-06       Impact factor: 4.147
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.